Byrne Asset Management’s Microbot Medical MBOT Stock Holding History

Byrne Asset Management’s Portfolio MBOT Stock Details MBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,800	Closed	-$5.06K	–	281
2023 Q3	$16K	Buy	+3,800	New	+$8.24K	0.01%	295

Other funds holding MBOT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $100M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Byrne Asset Management's MBOT Position: Q4 2023 in Review

Byrne Asset Management sold out of Microbot Medical (MBOT) in Q4 2023, closing a stake of 3,800 shares — an estimated $5.06K sold.

Byrne Asset Management first reported a position in MBOT in Q3 2023 and held it in 1 quarter. The position peaked at $16K in Q3 2023. 36 funds tracked by Wall St. Rank hold MBOT as of Q4 2023.

Byrne Asset Management reported no remaining Microbot Medical position as of Q4 2023 after selling out during the quarter.
Byrne Asset Management sold 3,800 Microbot Medical shares in Q4 2023, an estimated $5.06K.
Byrne Asset Management first reported a position in Microbot Medical in Q3 2023 and held it in 1 quarter.
Byrne Asset Management's Microbot Medical position peaked at $16K in Q3 2023.
36 funds tracked by Wall St. Rank held Microbot Medical as of Q4 2023.

Based on Byrne Asset Management's 13F filing for Q4 2023, filed 29 Jan 2024.